These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 21769761

  • 21. Cross-sectional analysis of sexual function after prostate brachytherapy.
    Finney G, Haynes AM, Cross P, Brenner P, Boyn A, Stricker P.
    Urology; 2005 Aug; 66(2):377-81. PubMed ID: 16098365
    [Abstract] [Full Text] [Related]

  • 22. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):463-71. PubMed ID: 16168838
    [Abstract] [Full Text] [Related]

  • 23. Sexual function after permanent 125I-brachytherapy for prostate cancer.
    Mabjeesh N, Chen J, Beri A, Stenger A, Matzkin H.
    Int J Impot Res; 2005 Oct 01; 17(1):96-101. PubMed ID: 15510186
    [Abstract] [Full Text] [Related]

  • 24. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.
    Teloken PE, Ohebshalom M, Mohideen N, Mulhall JP.
    J Urol; 2007 Dec 01; 178(6):2521-5. PubMed ID: 17937948
    [Abstract] [Full Text] [Related]

  • 25. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.
    Tanaka N, Fujimoto K, Hirao Y, Asakawa I, Hasegawa M, Konishi N.
    Urology; 2009 Aug 01; 74(2):407-11. PubMed ID: 19376570
    [Abstract] [Full Text] [Related]

  • 26. A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Matsushima M, Kikuchi E, Maeda T, Nakashima J, Sugawara A, Ando T, Mizuno R, Nagata H, Miyajima A, Shigematsu N, Oya M.
    J Urol; 2013 Mar 01; 189(3):1014-8. PubMed ID: 23017516
    [Abstract] [Full Text] [Related]

  • 27. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy.
    Köhler TS, Pedro R, Hendlin K, Utz W, Ugarte R, Reddy P, Makhlouf A, Ryndin I, Canales BK, Weiland D, Nakib N, Ramani A, Anderson JK, Monga M.
    BJU Int; 2007 Oct 01; 100(4):858-62. PubMed ID: 17822466
    [Abstract] [Full Text] [Related]

  • 28. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy.
    Solan AN, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Apr 01; 73(5):1468-74. PubMed ID: 18922652
    [Abstract] [Full Text] [Related]

  • 29. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T, Taussky D, Donath D, Le HP, Larouche RX, Béliveau-Nadeau D, Hervieux Y, Delouya G.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e377-83. PubMed ID: 21514068
    [Abstract] [Full Text] [Related]

  • 30. Factors influencing urinary symptoms 10 years after permanent prostate seed implantation.
    Stone NN, Gerber NK, Blacksburg S, Stone J, Stock RG.
    J Urol; 2012 Jan 15; 187(1):117-23. PubMed ID: 22114818
    [Abstract] [Full Text] [Related]

  • 31. Erectile dysfunction is predictive of all-cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy.
    Bittner N, Merrick GS, Galbreath RW, Butler WM, Lief JH, Allen ZA, Wallner KE.
    BJU Int; 2012 Jan 15; 109(2):220-5. PubMed ID: 21733074
    [Abstract] [Full Text] [Related]

  • 32. Nursing considerations in brachytherapy-related erectile dysfunction.
    Stipetich R, Abel LJ, Anderson RL, Butler WM, Wallner KE, Merrick GS.
    Urol Nurs; 2005 Aug 15; 25(4):249-54; quiz 259. PubMed ID: 16225341
    [Abstract] [Full Text] [Related]

  • 33. Defining sexual outcomes after treatment for localized prostate carcinoma.
    Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA.
    Cancer; 2002 Oct 15; 95(8):1773-85. PubMed ID: 12365027
    [Abstract] [Full Text] [Related]

  • 34. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
    Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M, Shinohara K.
    BJU Int; 2009 Sep 15; 104(5):600-4. PubMed ID: 19245439
    [Abstract] [Full Text] [Related]

  • 35. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.
    Prada PJ, Juan G, González-Suárez H, Fernández J, Jimenez I, Amón J, Cepeda M.
    BJU Int; 2010 Jul 15; 106(1):32-6. PubMed ID: 20067460
    [Abstract] [Full Text] [Related]

  • 36. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer.
    Stock RG, Kao J, Stone NN.
    J Urol; 2001 Feb 15; 165(2):436-9. PubMed ID: 11176391
    [Abstract] [Full Text] [Related]

  • 37. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 38. Proposal for a predictive model of erectile function after permanent (125)I prostate brachytherapy for localized prostate cancer.
    Huyghe E, Delaunay B, Njomnang Soh P, Delannes M, Walschaerts M, Delavierre D, Soulie M, Bachaud JM.
    Int J Impot Res; 2013 Jun 15; 25(4):121-6. PubMed ID: 23446806
    [Abstract] [Full Text] [Related]

  • 39. Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer.
    Wernicke AG, Valicenti R, Dieva K, Houser C, Pequignot E.
    Int J Radiat Oncol Biol Phys; 2004 Dec 01; 60(5):1357-63. PubMed ID: 15590165
    [Abstract] [Full Text] [Related]

  • 40. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer.
    Tharp M, Hardacre M, Bennett R, Jones WT, Stuhldreher D, Vaught J.
    Brachytherapy; 2008 Dec 01; 7(3):231-6. PubMed ID: 18579446
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.